Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16638620 | 0.97 | ALOX15 (0.41) | ALOX15KDM4EMAPTSMN1; SMN2BLM | |
| SCHEMBL16638646 | 0.97 | ALOX15 (0.41) | ALOX15KDM4EMAPTSMN1; SMN2BLM | |
| SCHEMBL899927 | 0.89 | TDP1 (0.37) | ALOX15KDM4EBLMPMP22KMT2A | |
| SCHEMBL3319762 | 0.86 | CYP1A2 (0.44) | ALOX15KDM4EMAPTSMN1; SMN2KMT2A | |
| SCHEMBL808456 | 0.86 | TDP1 (0.36) | ALOX15KDM4EBLMPMP22KMT2A | |
| SCHEMBL20998889 | 0.86 | TDP1 (0.36) | ALOX15KDM4EBLMPMP22KMT2A | |
| Ammonia Solution, Strong SCHEMBL10870270 | 0.86 | ALOX15 (0.35) | ALOX15KDM4EBLMPMP22KMT2A | |
| Hydrochloric Acid SCHEMBL9711107 | 0.86 | ALOX15 (0.35) | ALOX15KDM4EBLMPMP22KMT2A | |
| SCHEMBL16638621 | 0.84 | PAOX (0.31) | — | |
| Trolamine SCHEMBL14990729 | 0.83 | KDM4E (0.44) | ALOX15KDM4EMAPTSMN1; SMN2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074869-A1 | AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF | YIWUHUAYAO PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2025-03-06 | — | — | US | claimed |
| EP-4245750-A1 | AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF | YIWUHUAYAO PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2023-09-20 | — | — | EP | claimed |
| CN-112225673-B | Amino combretastatin derivative and application thereof | 义乌市华耀医药科技有限公司 | 2022-08-02 | — | — | CN | claimed |
| US-7803839-B2 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS, INC. (US) | 2010-09-28 | — | — | US | claimed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
| US-20250074869-A1 | AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF | YIWUHUAYAO PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2025-03-06 | — | — | US | disclosed |
| EP-4245750-A1 | AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF | YIWUHUAYAO PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2023-09-20 | — | — | EP | disclosed |
| CN-112225673-B | Amino combretastatin derivative and application thereof | 义乌市华耀医药科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-20210246344-A1 | Biological buffers with wide buffering ranges | DALY THOMAS (US) | 2021-08-12 | — | — | US | disclosed |
| US-20200071582-A1 | Biological Buffers with Wide Buffering Ranges | TPAT IP LLC | 2020-03-05 | — | — | US | disclosed |
| US-7442791-B2 | Aminoalkylamide substituted cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1667962-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005028427-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | LSS, CYP51A1, CYP46A1 | ALOX15 80/4885KDM4E 1625/4885MAPT 4552/4885 |
| US-20250074869-A1 | AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF | TUBB3, TUBB6, TUBA3C | ALOX15 4292/4885KDM4E 4395/4885MAPT 24/4885 |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | NRAS, BRAF, KRAS | ALOX15 985/4885KDM4E 913/4885MAPT 4202/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | ALOX15 2465/4885KDM4E 592/4885MAPT 3423/4885 |
| US-20200071582-A1 | Biological Buffers with Wide Buffering Ranges | PEF1, SLC7A1, PLPBP | ALOX15 3813/4885KDM4E 2858/4885MAPT 2799/4885 |
| US-20210246344-A1 | Biological buffers with wide buffering ranges | PEF1, SLC7A1, PLPBP | ALOX15 3788/4885KDM4E 2827/4885MAPT 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.